Literature DB >> 28332779

Intrafamilial phenotypic variability in a Polish family with Sensenbrenner syndrome and biallelic WDR35 mutations.

Joanna Walczak-Sztulpa1, Anna Wawrocka1, Agata Sobierajewicz1, Lukasz Kuszel1, Jan Zawadzki2, Ryszard Grenda2, Anna Swiader-Lesniak3, Beata Kocyla-Karczmarewicz4, Anna Wnuk5, Anna Latos-Bielenska1, Krystyna H Chrzanowska6.   

Abstract

Sensenbrenner syndrome (cranioectodermal dysplasia, CED) is a very rare autosomal recessive ciliopathy. Cranioectodermal dysplasia is characterized by craniofacial, skeletal, and ectodermal abnormalities. About 50 patients have been described to date. Sensenbrenner syndrome belongs to a group of ciliary chondrodysplasias and is a genetically heterogeneous disorder. Mutations in five genes: IFT122, WDR35, IFT43, WDR19, and IFT52 have been associated with CED. All known genes encode proteins that are part of the intraflagellar transport complex, which plays an important role in the assembly and maintenance of cilia. Here, we report a family with two children affected by Sensenbrenner syndrome, a 9-year-old girl and her older sister who died in infancy due to respiratory, liver, and renal insufficiency. Dysmorphic features included short stature with rhizomelic shortening of limbs, short fingers, preaxial polydactyly of left hand, narrow chest, craniosynostosis, dolichocephaly, high anterior hairline, epicanthal folds and telecanthus, depressed nasal bridge, low-set ears, and additional ectodermal abnormalities. The patient presented with chronic tubulointerstitial renal disease. She had abnormal echogenicity on renal ultrasound, reduced glomerular filtration, albuminuria and tubular proteinuria, hypocalciuria and hypocitraturia, accompanied by pre-hypertensive state. This pattern of renal abnormality was regarded as nephronophthisis. Psychomotor development was apparently normal. Molecular analysis in one of the affected individuals identified compound heterozygosity for a nonsense (c.1922T>G, p.(Leu641*)) and missense (c.2522A>T, p.(Asp841Val)) variants in WDR35. We present a detailed clinical descriptions of two female siblings showing an intrafamilial phenotypic variability of the disease, and illustrating the potential lethality of CED.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Sensenbrenner syndrome; WDR35; anthropometric measurements; chondrodysplasia; ciliopathy; progressive renal disease

Mesh:

Substances:

Year:  2017        PMID: 28332779     DOI: 10.1002/ajmg.a.38163

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  5 in total

1.  Sensenbrenner Syndrome Presenting with Severe Anorexia, Failure to Thrive, Chronic Kidney Disease and Angel-Shaped Middle Phalanges in Two Siblings.

Authors:  Miroslava Brndiarova; Martin Mraz; Zuzana Kolkova; Frantisek Cisarik; Peter Banovcin
Journal:  Mol Syndromol       Date:  2021-06-16

2.  A human ciliopathy with polycystic ovarian syndrome and multiple subcutaneous cysts: A rare case report.

Authors:  Kangan Tan; Peng Liu; Lili Pang; Wanna Yang; Fengqin Hou
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

3.  Compound heterozygous IFT140 variants in two Polish families with Sensenbrenner syndrome and early onset end-stage renal disease.

Authors:  Joanna Walczak-Sztulpa; Renata Posmyk; Ewelina M Bukowska-Olech; Anna Wawrocka; Aleksander Jamsheer; Machteld M Oud; Miriam Schmidts; Heleen H Arts; Anna Latos-Bielenska; Anna Wasilewska
Journal:  Orphanet J Rare Dis       Date:  2020-02-01       Impact factor: 4.123

4.  A novel combination of biallelic IFT122 variants associated with cranioectodermal dysplasia: A case report.

Authors:  Qi Yang; Qiang Zhang; Fei Chen; Shang Yi; Mengting Li; Sheng Yi; Xingmin Xu; Jingsi Luo
Journal:  Exp Ther Med       Date:  2021-02-01       Impact factor: 2.447

Review 5.  Ciliary Signalling and Mechanotransduction in the Pathophysiology of Craniosynostosis.

Authors:  Federica Tiberio; Ornella Parolini; Wanda Lattanzi
Journal:  Genes (Basel)       Date:  2021-07-14       Impact factor: 4.096

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.